USANA Health Sciences, Inc. announced its financial results for the fourth quarter and full year 2024. Total net sales in 2024 were $855 million, down from $921 million in 2023. Net earnings for the year were $42 million, compared to $63.8 million in 2023, with a diluted EPS of $2.12, down from $3.30 in 2023.
Net sales in the fourth quarter of 2024 were $214 million, down from $221 million in Q4 2023, while net earnings were $4.5 million, compared to $16.8 million.
In a $206 million deal, the company acquired a controlling stake (78.8%) of Hiya Health Products, LLC in the fourth quarter of 2024, describing Hiya as a “highly cash generative, direct-to-consumer children’s wellness brand” with a “compelling subscription business model” that the company believes will position USANA to deliver long-term sustainable growth.
“USANA delivered fourth quarter results above our internal expectations, highlighted by 7% sequential net sales growth,” said Jim Brown, USANA President and Chief Executive Officer. “Positive momentum in the Americas & Europe region generated year-over-year and sequential sales growth in this region while performance in our Asia Pacific region declined slightly and was in line with our expectations. On a consolidated basis, we generated solid cash flow during the quarter and our balance sheet remains in a healthy net cash position. Overall, we delivered solid performance to finish the year and are confident in our ability to build on this performance in 2025.”
The company now forecasts consolidated net sales for fiscal year 2025 between $920 million and $1 billion with net earnings between $29 million and $41 million, and ended 2024 with $182 million in cash and cash equivalents.
